MedTrace Logo

Novel Energy Metabolic Signaling Molecule With Therapeutic Potential

NCT04713319 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-10-26

No results posted yet for this study

Summary

Altogether a 25-day study. First 4 days non-blinded with water before 0-control blood samples (Day0). Thereafter blinded for 21 days (3 weeks). Study group was apparently healthy 50-60 -year-old males and females (N=27).

Conditions

  • Healthy Participants

Interventions

DRUG

Panavital

In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.

OTHER

Placebo

In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.

Sponsors & Collaborators

  • University of Jyvaskyla

    collaborator OTHER

  • Petteri Hirvonen

    lead INDUSTRY

Principal Investigators

  • Heikki Kyröläinen, PhD · University of Jyvaskyla

  • Petteri Hirvonen, M.Sc., MBA · University of Jyväskylä, Replicon Health Oy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04713319 on ClinicalTrials.gov